Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy

Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy

ABSTRACT Introduction Current guidelines do not mandate CD19 tumor expression assessment before chimeric antigen receptor T‐cell (CAR‐T) therapy in large B‐cell lymphoma (LBCL) patients due to limitations of immunohistochemistry (IHC) or flow cytometry. Quantitative polymerase chain reaction (qPCR)...

Full description

Saved in:
Bibliographic Details
Main Authors: Rafael Hernani, Laura Ventura, Begoña Heras, Alicia Serrano, Marcos Rivada, Carolina Martínez‐Ciarpaglini, Ana Benzaquén, Blanca Ferrer‐Lores, Ariadna Pérez, José Luis Piñana, Juan Carlos Hernández‐Boluda, Ignacio Arroyo, Paula Amat, Irene Pastor‐Galán, María José Remigia, Rosa Goterris, Montse Gómez, Anabel Teruel, Ana Saus, Consejo Ortí, María José Terol, Antonio Ferrández‐Izquierdo, Carlos Solano
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:eJHaem
Subjects:
CAR‐T therapy
large B‐cell lymphoma
CD19 tumor expression
quantitative PCR
Online Access:https://doi.org/10.1002/jha2.70015
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction Current guidelines do not mandate CD19 tumor expression assessment before chimeric antigen receptor T‐cell (CAR‐T) therapy in large B‐cell lymphoma (LBCL) patients due to limitations of immunohistochemistry (IHC) or flow cytometry. Quantitative polymerase chain reaction (qPCR) offers a more sensitive alternative for detecting CD19 expression, with the primary advantage that mRNA can be easily extracted from paraffin‐embedded tissues. Methods & Results In our study, we included 51 adult patients with LBCL treated with axicabtagene ciloleucel. Among them, 16 were classified as CD19‐negative by IHC; however, qPCR reclassified six (37.5%) as CD19‐positive. We then compared the outcomes between consistently CD19‐negative (IHC−qPCR−) and CD19‐positive (IHC+ and IHC−qPCR+) patients. CD19‐negative cohort showed worse 1‐year progression‐free survival (15 vs. 45%, p = 0.044) and a trend toward shorter duration of response (29 vs. 55%, p = 0.065). Only one (10%) of the CD19‐negative patients remained alive and disease‐free at last follow‐up (6 months), having previously responded to bridge therapy. Discussion If confirmed in a large patient cohort, these findings could form the basis for modifying current patient selection criteria. Consistently negative patients may be suboptimal candidates for anti‐CD19 CAR‐T therapy. Alternative therapeutic options, such as bispecific antibodies or polatuzumab‐based regimens, could be considered for this subset of patients.
ISSN:2688-6146

Similar Items